| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Section of Neurobiology, Yale University School of Medicine, New Haven, Connecticut 06510
Gliomas are the most common primary intracranial tumors. One extracellular matrix component that has been implicated in glial tumor biology is brain enriched hyaluronan binding (BEHAB)/brevican. In this study, the CNS-1 rat glioma cell line was transfected with a vector containing either a full-length BEHAB/brevican cDNA, a 5' insert encoding the NH2-terminal BEHAB/brevican cleavage product, or a 3' insert encoding the COOH-terminal cleavage product. As a control, CNS-1 cells were transfected with green fluorescent protein. Rats with intracranial grafts of BEHAB/brevican-transfected CNS-1 cells displayed significantly shorter survival times than did rats with CNS-green fluorescent protein intracranial grafts (P < 0.001). Histological examination showed that the BEHAB/brevican-transfected tumors were just as, if not more, aggressive than control tumors, even though the BEHAB/brevican tumors had been growing for only approximately two-thirds the time as long as control tumors. These data suggest that up-regulation and proteolytic cleavage of BEHAB/brevican increase significantly the aggressiveness of glial tumors. It will be important to investigate the effect of inhibiting cleavage of BEHAB/brevican in these cells and to determine the therapeutic potential of inhibiting BEHAB/brevican cleavage in gliomas.
This article has been cited by other articles:
|
|
 |
|
  M. Diehn, C. Nardini, D. S. Wang, S. McGovern, M. Jayaraman, Y. Liang, K. Aldape, S. Cha, and M. D. Kuo From the Cover: Identification of noninvasive imaging surrogates for brain tumor gene-expression modules PNAS, April 1, 2008; 105(13): 5213 - 5218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Viapiano, W. L. Bi, J. Piepmeier, S. Hockfield, and R. T. Matthews Novel Tumor-Specific Isoforms of BEHAB/Brevican Identified in Human Malignant Gliomas Cancer Res., August 1, 2005; 65(15): 6726 - 6733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liang, M. Diehn, N. Watson, A. W. Bollen, K. D. Aldape, M. K. Nicholas, K. R. Lamborn, M. S. Berger, D. Botstein, P. O. Brown, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme PNAS, April 19, 2005; 102(16): 5814 - 5819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Annabi, S. Thibeault, R. Moumdjian, and R. Beliveau Hyaluronan Cell Surface Binding Is Induced by Type I Collagen and Regulated by Caveolae in Glioma Cells J. Biol. Chem., May 21, 2004; 279(21): 21888 - 21896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Viapiano, R. T. Matthews, and S. Hockfield A Novel Membrane-associated Glycovariant of BEHAB/Brevican Is Up-regulated during Rat Brain Development and in a Rat Model of Invasive Glioma J. Biol. Chem., August 29, 2003; 278(35): 33239 - 33247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Brakebusch, C. I. Seidenbecher, F. Asztely, U. Rauch, H. Matthies, H. Meyer, M. Krug, T. M. Bockers, X. Zhou, M. R. Kreutz, et al. Brevican-Deficient Mice Display Impaired Hippocampal CA1 Long-Term Potentiation but Show No Obvious Deficits in Learning and Memory Mol. Cell. Biol., November 1, 2002; 22(21): 7417 - 7427. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
